Now comes the hard question, how will the US payer system afford it? "An August report from the nonprofit Institute for Clinical and Economic Review found that the treatment and similar gene-editing therapies for sickle cell disease would be cost-effective if priced between $1.35 million and $2.05 million. In the U.S., patients with the condition and their insurers pay on average between $1.6 million and $1.7 million…
[flagged]
Almost everyone has some sort of gene that isn't great. They might have a family history of Alzheimer's, maybe a family history or some sort of cancer, or bipolar disorder, or any other of 100 different serious illnesses. Humans would go extinct if we only allowed those with perfect genes to reproduce.
Oh, and with sickle cell, you're going to be in particularly hot water with suggestions like that given the fact it's mostly African Americans who have the gene.